Erica Tsang

A plug for our @ALLIANCE_org trial for patients with BRCA1/2 or PALB2 mutant pancreas cancer! #NCTN #PancChat @EileenMOReilly @KReissMD @MPishvaian @efratdotan @HKennecke @Aiims1742 @GillSharlene @PanCAN @BasserBRCA @FacingOurRisk

💬 "I’m glad my data will play a role in bringing hope to more cancer patients" 💬 Precision oncology has given Dan Murphy new hope. Now, he's sharing his story – and his data – to bring that hope to other patients. 🍁  Full story ▶ bit.ly/47Vmw4U

PASS-01 trial #PDAC #ASCO24 ➡️rand ph2 mFFX vs.GnP ➡️WGS/RNA/PDO/CTCs/ctDNA ✅PP PFS 5.5 (GnP) vs. 4.0mths (mFFX) ➡️PP ❌gBRCA/PALB2 >KRASWT in GnP ➡️MTB directed 2nd line ➡️ GnP remains a backbone for drug dvp ➡️basal-like unmet need Proud @AmberHabowski as translational leads

A special evening today: Dr. Pamela Munster gets endowed with Mariam Moghadam Safinia distinguished professorship in hereditary cancer research @UCSFCancer #breastcancer #Oncology #researchers

🍁 MAESTRO: A Pan-Canadian project to accelerate #precisionmedicine for #pancreaticcancer🍁 🩺 Sadly, #PancreaticCancer is one of the deadliest cancers 🩺 Today, patients have very few treatment options, and those that exist are often ineffective

@pmcancercentre looking forward to Cancer Genomics - Tumor Immunotherapy Program Annual Symposium on Friday Nov 10 in MaRS auditorium. Amazing line up of speakers 👏🔥 pm-genomics-IO-symposium.ca

RMC-6236 RAS-MULTI (ON) inhibitor ➡️promising activity in heavily pre-treated PDAC pts ➡️ORR 20% in 46 pts ➡️median time to response 1.4mths ➡️median time on tx 3.3 mths ✅ctDNA clearance >50% in 92% ➡️likely to need combinations but +exciting for PDAC #ESMO23 #PancreaticCancer

PREOPANC-2 ➡️FFX vs Gemrads in resectable/ early BR #PancreaticCancer ➡️no diff in resection rates/OS/toxicity ❓recurrence patterns ➡️Nb full dose FFX #ESMO23

Such an honor to work with this super phase I team of PIs ⁦@pmcancercentre⁩ every day is an exciting day ⁦@salawuta⁩ ⁦@EricaTsangMD⁩ ⁦@LB_AR⁩ #anna_spreafico ⁦@Philippe_Bedard⁩ 🍁🍁🍁

"Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer" commentary by Dr @EricaTsangMD and Dr Gallinger on our (@KReissMD) recent paper in @CCR_AACR aacrjournals.org/clincancerres/…

Always a treat to hear @Aiims1742 describe RAS signalling and differences in KRAS mutant alleles in #PancreaticCancer pathogenesis ➡️ integration of transcriptomics to interrogate TME and metabolomics #abstract4020 ✅ Differences certainly in G12D vs G12R

T-1 week until our next Perspectives session in Chicago! @HornLeora @DrDanielHeng @DrCBrezden @lab_rezvani @ca_chung @maddynaseemMD #asco2023 #womeninmedicine

@francescocay giving remarks as #AACRAMC President. Looking forward to our Professional Advancement Sessions for #ECRs #AACR23 @immunegirl @CampKatiee @KristinAltwegg

So proud of @iryxie and all the Scholar in Training awardees for their amazing science and hard work!! #AACR23 #AACRAMC @AACR_CEO @francescocay @immunegirl @CampKatiee @jameshan_sj

A great opportunity to support the next generation of cancer research @AACR the Undergraduate Student Poster Competition is open until 4PM #AACR23 #AACRGlobalScholars

I had the best of times hearing about the research projects presented in the undergraduate student caucus and poster competition. So much enthusiasm and talent packed in a room! Thank you to the #AACRAMC judges @KristinAltwegg @waynerlawrence @MathiasSeviiri @safamajeed

Thank you @women_in_cancer - Women in Cancer / All in Cancer for the Keynote invitation 🙏 ➡️ Strengthening through Perspectives 🗓️ Friday April 28th at 530pm EST Faculty Club, University of Toronto Join us 👉Register at womenincancer.com #HappyInternationalWomensDay @BCCancer @CAMO_ACOM @CDNCancerTrials @UBCDoM

Happy International Women’s Day! Come join us Women-in-Cancer for our new series “Strengthening through Perspectives” and engage with our growing international community! Register at womenincancer.com @DrCESimmons @DrCBrezden @HinaSaeedMD @IshwariaMD @belinda_campbe

📣Today is the day - come join us and @amykpatel to hear about "Professional Success in Social Media" at 6:30pm CT. DM for the Zoom link! #SoMe #oncology @ca_chung @maguy_farhat @EricaTsangMD @JodiGoldman20

Just published! A phase Ib trial of the PI3K inhibitor alpelisib and weekly cisplatin in patients with solid tumor malignancies. Read more in this study by @EricaTsangMD et al. bit.ly/3O6jsrU @UCSF #openaccess